FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 356:891-893 March 1, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective Perspective by Von Drygalski, A. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Von Drygalski, A. PubMed Citation

In 1949, Ackroyd reported the abrupt onset of severe thrombocytopenia and purpura in patients receiving the sedative allylisopropylacetylcarbamide (Sedormid).¹ All the patients had taken Sedormid previously and had become sensitized to it. Today, this classic picture of drug-induced, immune-mediated thrombocytopenia is most often caused by quinine in outpatients and by vancomycin in hospitalized patients, as discussed by Von Drygalski et al. in this issue of the Journal (pages 904–910).

In 1973, Rhodes, Dixon, and Silver described thrombocytopenia and thrombosis occurring a week after the initiation of heparin therapy and provided evidence of an immune pathogenesis for this complication of heparin . . . [Full Text of this Article]

Source Information

Dr. Warkentin is a professor of pathology and molecular medicine and medicine at the Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.

This article has been cited by other articles:

• (2007). Vancomycin-Induced Thrombocytopenia. JWatch Oncology and Hematology 2007: 1-1 [Full Text]  
• (2007). It's Confirmed: Vancomycin Causes Immune Thrombocytopenia. JWatch General 2007: 3-3 [Full Text]